Diosgenin ameliorates behavioral alterations, hippocampal oxidative stress markers, and apoptotic deficits in a rat model of autism induced by valproic acid.

Researchers tested a natural compound called diosgenin in rats that showed autism-like behaviors. The rats were given this compound for about a month, then tested on social skills, repetitive behaviors, and memory. Results showed the compound helped improve memory problems and reduced repetitive behaviors. It also protected brain cells from damage and reduced harmful chemicals in the brain. While promising, this is early research in animals, not humans.

This preclinical study investigated diosgenin, a plant-derived compound, in rats with autism-like behaviors induced by valproic acid exposure. Male rat offspring received diosgenin treatment from postnatal day 23-52 and underwent behavioral testing including social interaction, repetitive behaviors, and memory tasks. The study measured oxidative stress markers, cell death indicators, and brain tissue changes in the hippocampus. Results showed that diosgenin treatment improved recognition memory, reduced repetitive/anxiety-like behaviors, decreased oxidative stress markers, reduced cell death indicators, and protected hippocampal neurons.

The findings suggest diosgenin may have neuroprotective properties in this autism model, potentially through reducing brain inflammation and protecting nerve cells from damage.

While promising for neuroprotection and behavioral improvement in autism models, human clinical trials are needed before considering therapeutic applications. The compound's effects on oxidative stress and neuronal protection warrant further investigation in autism research.

This is a preclinical animal study using an induced autism model, which may not fully represent human autism. Small sample sizes for biochemical analyses (n=3) limit statistical power. No comparison to established autism treatments. Long-term effects and safety profile unknown.

Autism Spectrum Disorder (ASD) is characterized by difficulties in social communication, anxiety, and repetitive behaviors, and it may also be associated with cognitive memory impairment. The etiology of ASD is complex, and current treatments have limited efficacy in addressing all ASD-related symptoms. Diosgenin (Dios) has shown neuroprotective effects in various neurological conditions. This study aimed to investigate the effects of Dios on hippocampal oxidative stress, apoptosis, and behavioral outcomes in a Valproic acid (VPA) induced rat model of Autism.

We examined the potential role of Dios in altering recognition memory behaviors in male rats prenatally exposed toVPA (600 mg/kg). The offspring received Dios (40 mg/kg) or Carboxymethyl cellulose (5 mg/kg) from postnatal day (PND) 23 to PND 52. Subsequently, these animals were tested with behavioral tests, including the Three-Chamber, Marble Burying, Open Field, and Passive Avoidance tests (n=8). Additionally, reactive oxygen species (ROS) markers (GSH, CAT, ROS, n=3), apoptotic markers (Caspase3, Bax, Bcl-2, n=3), and histological evaluations (Nissl staining) were performed.

VPA-exposed rats displayed Autism-like behavioral impairments, including deficits in recognition memory and increased repetitive/anxiety-like behaviors. Additionally, Caspase-3 and Bax were upregulated, and Bcl2 was downregulated in hippocampal tissues. The rats in the study displayed a reduced antioxidant function, as shown by the decreased levels of GSH and CAT. Treatment with Dios mitigated markers of apoptosis and ROS, and enhanced recognition memory behavior in rats exposed to VPA.

Furthermore, those treated with Dios exhibited a decrease in dark cell rates in the CA1 region of the hippocampus. This study demonstrated that markers of apoptosis and oxidative stress are elevated in rats exposed to VPA. The administration of Dios significantly reduces these markers, which in turn alleviates neuronal damage in the hippocampus and behavioral symptoms. Overall, these findings provide preclinical evidence supporting the potential neuroprotective role of Dios in an experimental model of ASD.